No Data
Is Now The Time To Put Puma Biotechnology (NASDAQ:PBYI) On Your Watchlist?
SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why
With 49% Stake, Puma Biotechnology, Inc. (NASDAQ:PBYI) Seems to Have Captured Institutional Investors' Interest
Puma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results
Puma Biotechnology's NERLYNX Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer With a HER2 Mutation